Hans van Houte, Chief Financial Officer at Nurix Therapeutics, Inc. (NRIX), sold 14,055 shares at $16.58 ($233K) on 2026-05-05, disclosed to the SEC on 2026-05-05.
Scheduled sale ($233k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.58 | 13,473 | $223K | 95.7% |
| 2 | $17.18 | 582 | $10K | 4.3% |
| Total | $16.60 avg | 14,055 | $233K | 100% |
| Filing → |
| NRIX | SELL | 2026-04-30 | $40K | — | Filing → |
| NRIX | SELL | 2026-01-30 | $122K | — | Filing → |
| NRIX | SELL | 2025-11-03 | $158K | — | Filing → |